FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Trial details
- Registry ID
- NCT07446322
- Phase
- Phase 2
The FDA approved Bevacizumab (Avastin) on 26 Feb 2004.
Drug identity checked against registry records
Also recorded as Avastin
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2004-02-26Day | Bevacizumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125085", "applicant_as_listed_by_fda": "GENENTECH", "brand_names": ["AVASTIN"], "active_ingredients": ["BEVACIZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20040226", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |